SCHEMBL23484591

SCHEMBL23484591

O=C(Cc1ccc(Cl)cc1)Cc1ccc(-c2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.50
AKR1C2 P52895 1/20 0.47
AKR1C1 Q04828 1/20 0.47
DHODH Q02127 2/20 0.45
VNN1 O95497 1/20 0.44
TRPV1 Q8NER1 2/20 0.44
SERPINE1 P05121 1/20 0.44
NLRP3 Q96P20 1/20 0.44
PANK3 Q9H999 1/20 0.44
AURKA O14965 1/20 0.43
TPX2 Q9ULW0 1/20 0.43
LTA4H P09960 1/20 0.43
EPHX2 P34913 1/20 0.43
P2RY14 Q15391 1/20 0.43
ACHE P22303 1/20 0.43
P2RX3 P56373 1/20 0.42
MGLL Q99685 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816202 0.92 VNN1 (0.49) PPARAAKR1C2AKR1C1VNN1SERPINE1
SCHEMBL2251955 0.81 VNN1 (0.51) VNN1TRPV1NLRP3PANK3LTA4H
SCHEMBL23484592 0.79 PPARG (0.48) PPARAAKR1C2AKR1C1
SCHEMBL23484657 0.78 GAA (0.46) PPARA
SCHEMBL20351686 0.78 HRH3 (0.52) VNN1NLRP3LTA4HEPHX2ACHE
SCHEMBL12731531 0.78 VNN1 (0.48) VNN1NLRP3PANK3LTA4HEPHX2
SCHEMBL1462002 0.77 NLRP3 (0.50) VNN1TRPV1NLRP3PANK3LTA4H
SCHEMBL2096216 0.77 SLC6A4 (0.49) TRPV1LTA4HP2RX3MGLL
SCHEMBL1479915 0.76 NPC1 (0.55)
SCHEMBL255564 0.76 CCR6 (0.50) PPARADHODHTRPV1EPHX2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT PPARA 1871/4885AKR1C2 364/4885AKR1C1 385/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT PPARA 1871/4885AKR1C2 364/4885AKR1C1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.